Numbers first: reflux · orforglipron · TRIUMPH-3.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
What is the correct interpretation, and what is the common misreading?
Look at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.
Nausea incidence in the pivotal trials runs to roughly 40 to 45 per cent at the higher doses against 15 to 20 per cent on placebo, with vomiting at roughly 15 to 25 per cent against 5 to 8 per cent. Discontinuation specifically attributable to gastrointestinal adverse events was in the range of 4 to 7 per cent. Those are the numbers to hold in mind when someone describes their experience as unusual.
| Feature | Local reaction | Sterile abscess | Cellulitis |
|---|---|---|---|
| Onset | Hours to 2 days | Days | 1–4 days, progressive |
| Warmth | Absent or minimal | Mild | Marked |
| Expansion | Static or shrinking | Slow | Expanding |
| Texture | Firm, flat or raised | Fluctuant | Diffuse, indurated |
| Systemic features | None | None | Fever, malaise possible |
| Action | Observe, rotate site | Clinical review | Same-day clinical review |
Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
The caveat that actually matters: this is pattern recognition from published data, not a clinical assessment of you. Anything severe, persistent or accompanied by systemic features belongs with a clinician the same day.
Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsTiming is the most useful diagnostic feature here and it is the one most often omitted from the question.
Distinguishing an injection-site nodule from an infection: a nodule is firm, non-tender or mildly tender, not warm, not expanding, and appears within a day or two. Cellulitis is warm, tender, expanding, and often accompanied by systemic features. A sterile abscess sits between the two and is fluctuant. Warmth plus expansion plus fever is the combination that stops being a forum question.
Specifically, pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.
If the timing does not fit the escalation, look for another explanation before settling on the drug.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.